Our Pricing

Mounjaro vs Saxenda: Private Prescription UK

Published on: June 03, 2026

Choosing between Mounjaro vs Saxenda for a UK prescription requires understanding how these two injectable weight loss treatments differ in mechanism, efficacy, and suitability. At Cured Pharmacy, our UK-registered clinical team provides transparent comparisons and personalised prescriber assessments to help you access the most appropriate treatment, with prices starting from £135.00 for Saxenda and £135.00 for Mounjaro.

How Mounjaro and Saxenda Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. This dual-action mechanism activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, enhancing insulin secretion, slowing gastric emptying, and reducing appetite through complementary pathways.

Saxenda, by contrast, contains liraglutide, a single GLP-1 receptor agonist that has been available in the UK since 2015 [2]. Liraglutide mimics the natural GLP-1 hormone to regulate blood sugar and suppress appetite, but operates through one pathway rather than two. Both treatments require subcutaneous injection and work by altering the hormonal signals that control hunger and satiety, though their pharmacological profiles differ substantially.

Clinical Efficacy: Mounjaro vs Saxenda Weight Loss Results

In head-to-head clinical comparisons, tirzepatide consistently demonstrates superior weight reduction outcomes. The SURMOUNT-1 trial showed patients taking the 15mg Mounjaro dose achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. For context, the SCALE Obesity and Prediabetes trial found liraglutide 3mg (Saxenda) produced an average weight loss of 8.4% over 56 weeks versus 2.8% with placebo [2].

While individual responses vary based on adherence, baseline metabolic health, and lifestyle factors, the dual-receptor mechanism of tirzepatide appears to produce greater average reductions in body weight across clinical populations. Both medications require ongoing treatment to maintain weight loss, and discontinuation typically results in weight regain [3]. Your UK prescriber will assess which treatment aligns with your weight loss goals, medical history, and tolerance for injection frequency.

Real-World Effectiveness in UK Patients

Clinical trial results represent controlled conditions, but real-world effectiveness depends on consistent adherence, dietary modifications, and physical activity. UK prescribers at Cured Pharmacy emphasise that both Mounjaro and Saxenda work best when combined with a reduced-calorie diet and increased exercise, as outlined in NICE guidance for obesity management [4]. Neither medication is a standalone solution, and patients who engage with structured lifestyle programmes typically achieve better long-term outcomes.

Dosing and Administration: Weekly vs Daily Injections

Mounjaro is administered once weekly using a pre-filled KwikPen injector, starting at 2.5mg and gradually increasing to a maintenance dose of 5mg, 10mg, or 15mg based on individual response and tolerability [1]. The weekly schedule offers convenience for patients who prefer fewer injections, though the dose escalation period typically spans 8 to 20 weeks to minimise gastrointestinal side effects.

Saxenda requires daily subcutaneous injection, beginning at 0.6mg and increasing by 0.6mg increments weekly until reaching the maintenance dose of 3mg daily [2]. The daily regimen provides more frequent dosing touchpoints, which some patients find helpful for routine adherence, while others prefer the simplicity of weekly administration. Both pens are designed for self-injection into the abdomen, thigh, or upper arm, and UK prescribers provide full injection technique guidance during your consultation.

Side Effects and Tolerability Comparison

Both Mounjaro and Saxenda share a common side effect profile dominated by gastrointestinal symptoms, including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort [1][2]. These effects are most pronounced during dose escalation and typically diminish over several weeks as the body adapts. In clinical trials, approximately 44% of tirzepatide patients and 39% of liraglutide patients experienced nausea, though severe cases leading to discontinuation were less common.

Rarer but serious adverse effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking concurrent diabetes medications). Both treatments carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, and neither should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3]. Your UK prescriber will review your full medical history to identify any contraindications before issuing a prescription.

Managing Side Effects During Treatment

UK clinical guidance recommends eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated to mitigate gastrointestinal symptoms. If side effects become intolerable, your prescriber may adjust the dose escalation schedule or consider switching treatments. Superintendent pharmacist Tarun Kumar (GPhC 2233073) and the Cured Pharmacy clinical team provide ongoing support throughout your treatment journey, ensuring any concerns are addressed promptly.

Cost and Accessibility: Private Prescription Pricing UK

At Cured Pharmacy, Mounjaro is available from £124.99 per pen, with final cost determined by your prescribed dose and treatment duration. Saxenda starts from £135.00 reflecting its longer market presence and different dosing structure. Both medications require a private prescription in the UK, as they are not routinely available on the NHS for weight management outside specific specialist services.

Transparent upfront pricing is a core principle at Cured Pharmacy — you'll see exact costs before completing your free online consultation, with no hidden fees or surprise charges. Our UK-registered prescribers assess your eligibility based on BMI, comorbidities, and previous weight loss attempts, ensuring you receive a clinically appropriate recommendation rather than a sales-driven decision. All treatments are dispensed as genuine UK-licensed medicines with full regulatory approval.

Which Treatment Is Right for You?

Choosing between Mounjaro and Saxenda depends on your weight loss targets, tolerance for injection frequency, budget, and individual response to GLP-1 therapies. Patients seeking maximum weight reduction and willing to invest in newer dual-agonist technology may prefer Mounjaro, while those prioritising lower upfront cost or familiarity with established treatments may opt for Saxenda.

Your UK prescriber will evaluate your BMI (typically ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities), previous weight management efforts, and any contraindications such as diabetic retinopathy or severe gastrointestinal disease [4]. If one treatment is unsuitable or poorly tolerated, alternatives like Wegovy (semaglutide) or oral options such as Orlistat may be considered. The consultation process at Cured Pharmacy takes under three minutes, with prescriptions issued the same day subject to clinical approval.

Starting Your Weight Loss Journey at Cured Pharmacy

Begin by completing our free online assessment, which asks about your medical history, current medications, and weight loss goals. A UK-registered prescriber reviews your submission and determines the most suitable treatment, issuing a prescription if clinically appropriate. Your medication is then dispensed by our GPhC-registered pharmacy (9012511) and delivered in 100% discreet packaging, typically within 1-3 working days across the UK.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro and Saxenda are prescription-only medicines that must be prescribed following a consultation with a registered UK clinician who will assess your suitability based on your individual medical history and weight management needs.